Zai Lab Reports Topline Data From Phase 3 Bridging Trial Evaluating KarXT For Schizophrenia In China; KarXT Demonstrated A Statistically Significant 9.2-Point Reduction In PANSS Total Score From Baseline At Week 5 Compared To Placebo, Trial Met All...

再鼎醫藥報道了在中國評估KarXt用於精神分裂症的3期過渡試驗的上市數據；與安慰劑相比，KarXt在第5周的PANSS總分從基線顯著減少了9.2分，試驗達到了所有目標。

Benzinga · 10/29 19:39

Zai Lab Reports Topline Data From Phase 3 Bridging Trial Evaluating KarXT For Schizophrenia In China; KarXT Demonstrated A Statistically Significant 9.2-Point Reduction In PANSS Total Score From Baseline At Week 5 Compared To Placebo, Trial Met All Secondary Endpoints

再鼎醫藥報道了在中國評估KarXt用於精神分裂症的3期過渡試驗的上市數據；與安慰劑相比，KarXt在第5周的PANSS總分從基線顯著減少了9.2分，試驗達到了所有次要終點。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。